Evaluation of 627 in Healthy Adult Subjects

Phase 1 Not yet recruiting 108 enrolled Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose phase I clinical study to evaluate the safety, tolerability, PK and immunogenicity of SSGJ-627 in healthy adult subjects after single subcutaneous injection.

Timeline

Start: 2025-07-20
Primary completion: 2026-09-18
Completion: 2026-09-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	627	Unknown	—	Subcutaneous

Indications

No indication recorded.